The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications
Open accessAbstract
Liposomes are lipid based vesicular systems that offer novel platform for versatile drug delivery to target cell. Liposomes were first reported by Bangham and his co-workers in 1964 (1). Since then, liposomes have undergone extensive research with the prime aim to optimize encapsulation, stability, circulation time and target specific drug delivery. Manipulation of a liposome’s lipid bilayer and surface decoration with selective ligands has transformed conventional liposomes into adaptable and multifunctional liposomes. Development of liposomes with target specificity provide the prospect of safe and effective therapy for challenging clinical applications. Bioresponsive liposomes offer the opportunity to release payload in response to tissue specific microenvironment. Incorporation of novel natural and synthetic materials has extended their application from stable formulations to controlled release targeted drug delivery systems. Integration and optimization of multiple features into one system revolutionized research in the field of cancer, gene therapy, immunotherapy and infectious diseases. After 50 years since the first publication, this review is aimed to highlight next generation of liposomes, their preparation methods and progress in clinical applications. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Park, J. E., Tan, H. S., Datta, A., Lai, R. C., Zhang, H., Meng, W., Lim, S. K., & Sze, S. K. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900381-mcp200 · Cited by 582
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
Amstad, E., Kohlbrecher, J., Müller, E., Schweizer, T., Textor, M., & Reimhult, E. (2011) · Nano Letters · doi:10.1021/nl2001499 · Cited by 397
Federman, N., Chan, J., Nagy, J. O., Landaw, E. M., McCabe, K., Wu, A. M., Triche, T., Kang, H., Liu, B., Marks, J. D., et al. (2012) · Sarcoma · doi:10.1155/2012/126906 · Cited by 44
Cited by
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Biomedical applications of nanotechnology
Ramos, A. P., Cruz, M. A. E., Tovani, C. B., & Ciancaglini, P. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0246-2 · Cited by 413
Lipid-based nanocarriers for oral peptide delivery
Niu, Z., Conejos-Sánchez, I., Griffin, B. T., O’Driscoll, C. M., & Alonso, M. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.001 · Cited by 265
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Metadata
- Authors
- Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., Tahir, N., Ijaz, S., Al-Kassas, R., & Löbenberg, R.
- Venue
- Journal of Pharmacy & Pharmaceutical Sciences
- Publisher
- Frontiers Media SA
- Published
- 2014-08-26
- Volume
- 17
- Issue
- 3
- Pages
- 401
- ISSN
- 1482-1826 (ISSN-L)
- OpenAlex
- W1929522868
- Cited by
- 176
- References
- 5
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.